期刊
EXPERT OPINION ON DRUG SAFETY
卷 15, 期 1, 页码 117-129出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14740338.2016.1122755
关键词
allergic rhinitis; azelastine; Dymista; fluticasone propionate; MP29-02; safety
资金
- ALK-Abello
- Allergopharma
- Bionorica
- Dr. Pfleger
- Stallergenes
- HAL
- Artu Biologicals
- Allergy Therapeutics/Bencard
- Hartington
- Lofarma
- MEDA
- MSD
- Novartis/Leti
- ROXALL
- GSK
- Essex-Pharma
- Cytos
- Curalogic
- UK National Health Service
- British Lung Foundation
- Aerocrine
- AKL Ltd
- Almirall
- AstraZeneca
- Boehringer Ingelheim
- Chiesi
- Eli Lilly
- GlaxoSmithKline
- Merck
- Mundipharma
- Napp
- Novartis
- Orion
- Pfizer
- Respiratory Effectiveness Group
- Takeda
- Teva
- Zentiva
- Cipla
- Kyorin
- SkyePharma
- Medical Research Council
- Efficacy and Mechanism Evaluation programme
Introduction: As a chronic disease, allergic rhinitis (AR) requires regular use of allergy medications for the effective management of symptoms. It is therefore imperative that AR treatments not only provide adequate symptom control but are also well tolerated.Areas covered: MP29-02 (Dymista, Meda, Solna, Sweden) is the first new class of AR medication (WHO ATC R01AD58) since the introduction of intranasal corticosteroids (INS) almost 50years ago. It is a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate delivered in a single spray. Here we review all the safety information relevant to MP29-02, from the initial phase I bioavailability and disposition data, to the phase III 14-day and 52-week data and finally to phase IV safety data collected during MP29-02 use in routine clinical practice.Expert opinion: MP29-02 is the first real therapeutic advance in AR since the introduction of INS and has the potential to change the way this disease is managed, simplifying AR treatment regimens to a single puff in each nostril twice a day. Patients will benefit from superior symptom relief MP29-02 compared to INS with the added assurance that the safety of MP29-02 has been confirmed in the short term and long term as well as in real life.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据